| Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma. (NCT07616362) | Federation Francophone de Cancerologie Digestive | 2026-06-01 |
| Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer (NCT07150403) | Federation Francophone de Cancerologie Digestive | 2025-12-31 |
| Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma (NCT07270991) | Federation Francophone de Cancerologie Digestive | 2025-12-15 |
| PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma (NCT07128290) | Federation Francophone de Cancerologie Digestive | 2025-10-30 |
| 5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab (NCT07124884) | Federation Francophone de Cancerologie Digestive | 2025-08-31 |
| A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers (NCT06541652) | Federation Francophone de Cancerologie Digestive | 2024-03-26 |
| Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA (NCT06207981) | Federation Francophone de Cancerologie Digestive | 2024-02-26 |
| Prospective National Cohort Evaluating Predictive Biomarkers of Resistance to Immunotherapy in Patients With MSI/dMMR Metastatic Colorectal Cancer (CORESIM) (NCT06353854) | Federation Francophone de Cancerologie Digestive | 2024-02-12 |
| Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy (NCT05665348) | Federation Francophone de Cancerologie Digestive | 2023-03-09 |
| Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer (NCT05706779) | Federation Francophone de Cancerologie Digestive | 2023-02-13 |
| Cohort of Tumors With POLE/D1 Mutation (NCT05103969) | Federation Francophone de Cancerologie Digestive | 2021-10-05 |
| Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate (NCT04262687) | Federation Francophone de Cancerologie Digestive | 2021-04-06 |
| Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer (NCT04659382) | Federation Francophone de Cancerologie Digestive | 2020-10-07 |
| The GCO-002 CACOVID-19 Cohort: a French Nationwide Multicenter Study of COVID-19 Infected Cancer Patients (NCT04397575) | Federation Francophone de Cancerologie Digestive | 2020-04-03 |
| Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma (NCT03959293) | Federation Francophone de Cancerologie Digestive | 2019-07-17 |
| Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma (NCT03719924) | Federation Francophone de Cancerologie Digestive | 2019-03-07 |
| Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients (NCT03760822) | Federation Francophone de Cancerologie Digestive | 2018-11-16 |
| FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation (NCT03584711) | Federation Francophone de Cancerologie Digestive | 2018-04-26 |
| Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (NCT03186326) | Federation Francophone de Cancerologie Digestive | 2018-04-24 |